PMCB (PharmaCyte Biotech) Research & Development: $0.46 Mil (TTM As of Jan. 2026)


PMCB PharmaCyte Biotech Inc PMCB
32 GF Score
Price $0.76
! 2 Warning Signs
View Full Analysis

What is PharmaCyte Biotech Research & Development?

PharmaCyte Biotech PMCB -0.30% 32 Research & Development is $0.46 Mil as of Jan. 2026. GuruFocus rates PMCB with a GF Score™ of 32/100. The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. PharmaCyte Biotech's Research & Development for the three months ended in Jan. 2026 was $0.09 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jan. 2026 was $0.46 Mil.

PharmaCyte Biotech  (NAS:PMCB) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

PharmaCyte Biotech Research & Development Related Terms

PharmaCyte Biotech Research & Development Historical Data

* Premium members only.

The historical data trend for PharmaCyte Biotech's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PharmaCyte Biotech Research & Development Chart

PharmaCyte Biotech Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.92 0.69 0.47 0.41 0.44

PharmaCyte Biotech Quarterly Data
Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.12 0.13 0.10 0.14 0.09
PMCB
32GF Score
PharmaCyte Biotech Inc PMCB
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PharmaCyte Biotech Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jan. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.46 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $0.46 Mil mean?
PharmaCyte Biotech (PMCB) has a Research & Development of $0.46 Mil as of Jan. 2026. Research and development expense is the total cost for research and development activities. View historical data on PharmaCyte Biotech and its competitors.
Is PharmaCyte Biotech's Research & Development too high?
PharmaCyte Biotech's current Research & Development is $0.46 Mil. Overall, PharmaCyte Biotech has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does PharmaCyte Biotech's Research & Development compare to IMNN and ACXP?
PharmaCyte Biotech's Research & Development of $0.46 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on PharmaCyte Biotech and its competitors. PharmaCyte Biotech's current Research & Development is $0.46 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaCyte Biotech stock overvalued right now?
PharmaCyte Biotech (PMCB) has a current Research & Development of $0.46 Mil. The current Research & Development is $0.46 Mil. PharmaCyte Biotech's overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For PharmaCyte Biotech (PMCB), the current Research & Development is $0.46 Mil as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PharmaCyte Biotech Business Description

Address 3960 Howard Hughes Parkway, Suite 500, Las Vegas, NV, USA, 89169
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
32GF Score

Get the complete analysis for PMCB

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.76
Price